
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PTG-630
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : National Eye Institute
Deal Size : $0.3 million
Deal Type : Funding
Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy
Details : Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 01, 2023
Lead Product(s) : PTG-630
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : National Eye Institute
Deal Size : $0.3 million
Deal Type : Funding
